西格列汀降低受抑制HIV感染炎症与免疫激活的随机双盲安慰剂对照试验
这项多中心随机双盲安慰剂对照试验纳入病毒学抑制且无糖尿病的HIV成人感染者,比较西格列汀100 mg/日与安慰剂共16周对血浆sCD14变化的影响。
要点
- 西格列汀16周未改变病毒学抑制HIV感染者的sCD14水平
- 西格列汀组CXCL10较安慰剂组多下降47%(95%CI -57%至-35%)
- 西格列汀耐受良好,但其他可溶性标志物及免疫激活标志物无显著组间差异
核心结论
- 16周西格列汀对病毒学抑制HIV感染者的sCD14水平无影响。
- 西格列汀显著降低CXCL10,提示DPP-4抑制可能减少治疗HIV感染的心血管疾病风险。
研究设计与样本
- 多中心随机双盲安慰剂对照试验,纳入病毒学抑制、无糖尿病、稳定ART且CD4≥100/μL的HIV成人感染者。
- 随机分配至西格列汀100 mg/日或安慰剂共16周,主要终点为基线至第15-16周血浆sCD14变化。
主要发现
- 其他可溶性标志物、总CD4和CD8计数及淋巴细胞或单核细胞激活标志物均无显著组间差异。
- 西格列汀耐受良好。
临床怎么用
- 对于病毒学抑制的HIV感染者,西格列汀不宜以降低sCD14为目标使用。
- 西格列汀对CXCL10的显著降低作用提示其可能有助于减少心血管疾病风险,但需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors have pleotropic anti-inflammatory and immune regulatory effects in addition to glucoregulation. We evaluated inflammation and immune markers in suppressed human immunodeficiency virus (HIV) infection during treatment with the DPP-4 inhibitor sitagliptin. METHODS: Virologically suppressed adults with HIV without diabetes on stable antiretroviral therapy (ART) with ≥100/μL CD4 cells were randomized to 16 weeks of sitagliptin 100 mg/day vs placebo in a multicenter trial. The primary endpoint was the change in plasma soluble CD14 (sCD14) from baseline to week 15-16. RESULTS: Ninety participants were randomized, and 42 from each arm were included in per-protocol analyses. Participants were 45% non-Hispanic white, 38% non-Hispanic black, and 15% Hispanic, with a median age of 51 years; 83% were male; and the median CD4 count was 602 cells/μL. At week 15-16, there was no difference in sCD14 change between the 2 arms (P = .69). Relative to placebo, the sitagliptin arm had 47% greater decline in CXCL10 (95% confidence interval, -57% to -35%) at week 15 (P < .001). There were no significant between-arm differences in other soluble biomarkers, total CD4 and CD8 counts, or markers of lymphocyte or monocyte activation. Sitagliptin was well tolerated. CONCLUSIONS: Sixteen weeks of sitagliptin had no effect on sCD14 levels in virologically suppressed participants with HIV. CXCL10, a chemokine involved in atherogenesis that predicts non-AIDS events during ART, declined markedly with sitagliptin. This suggests that DPP-4 inhibition has the potential to reduce cardiovascular morbidity in treated HIV infection. CLINICAL TRIALS REGISTRATION: NCT01426438.
引用
- Dubé MP, Chan ES, Lake JE, et al. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection. Clin Infect Dis. 2019. PMID: 30535188. doi:10.1093/cid/ciy1051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。